However, in another retrospective study, TP53 alterations (mutations and/or copy number alterations) were still associated with inferior CR and OS rates in R/R DLBCL treated with CD19-CAR-T treatment (33). Here, CD19 is linked to diffuse large B-cell lymphoma.